Bausch Health has entered into an agreement with Allegro Ophthalmics to acquire an option to purchase all of Allegro’s ophthalmology assets, according to a press release.
The option includes global rights for Luminate (risuteganib), an investigational retina compound that acts on angiogenic, inflammatory and mitochondrial metabolic pathways in dry age-related macular degeneration. It also includes ALG-1007, a topical integrin regulator under investigation for the treatment of dry eye disease outside of the U.S.
“As part of the ongoing transformation of Bausch Health, we continue to
Uncategorized